MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-Catenin
2026-07-15
This study reveals that matrix metalloproteinase 7 (MMP7) directly promotes epithelial–mesenchymal transition (EMT) and liver fibrosis in biliary atresia (BA) by targeting the E-cadherin/β-catenin pathway. The findings identify MMP7 as a key molecular driver of fibrogenesis in pediatric liver disease and a potential target for novel anti-fibrotic therapies.
GSK-923295: CENP-E Inhibitor Workflows for Mitotic Fidelity
2026-07-15
GSK-923295 enables targeted disruption of mitotic kinesin CENP-E, empowering researchers to probe cell cycle arrest and chromosome alignment with high precision. This guide translates the latest insights in centromere biology and practical assay design, delivering actionable protocols and troubleshooting for advanced cancer models.
DDI2-NFE2L1-Proteasome Activation Shields Cells from Ferropt
2026-07-14
This study reveals that activation of the DDI2-NFE2L1 axis is essential for restoring proteasome function and protecting cells from ferroptosis. The findings provide mechanistic insight into protein homeostasis during oxidative stress and identify DDI2 as a potential therapeutic target for sensitizing cells to regulated cell death in cancer research.
ICG001: Advancing Wnt/β-Catenin Inhibition for Fibrosis and
2026-07-14
Explore how ICG001, a selective Wnt/β-catenin pathway inhibitor, empowers translational researchers to dissect CBP/β-catenin signaling in fibrosis and epithelial–mesenchymal transition (EMT), offering mechanistic clarity and strategic guidance for disease modeling. This article integrates recent findings on MMP7-mediated EMT in liver fibrosis, actionable protocol insights, and a vision for next-generation translational workflows.
Carboxylesterase Interference in Mitochondrial H2O2 Detectio
2026-07-13
This study identifies a critical source of error in mitochondrial hydrogen peroxide (H2O2) detection assays using Amplex Red. The authors demonstrate that carboxylesterases rapidly convert Amplex Red to resorufin independent of H2O2, potentially distorting measurements of mitochondrial reactive oxygen species. The findings urge researchers to reconsider the specificity of common oxidative stress assays and offer solutions for more accurate quantification.
Dabigatran Etexilate: Advancing Oral Anticoagulation in VTE
2026-07-13
The reference study establishes dabigatran etexilate as the first oral direct thrombin inhibitor to offer rapid, predictable anticoagulation without the frequent monitoring required by warfarin or the parenteral administration of low-molecular-weight heparins. This innovation holds particular value for improving the safety and accessibility of thromboprophylaxis in patients at risk for stroke or venous thromboembolism.
Synthetic Lethality via Mcl-1 and BCL-XL Inhibition in Gliob
2026-07-12
This study demonstrates that epigenetic suppression of Mcl-1, combined with pharmacological inhibition of BCL-XL/BCL-2, induces synthetic lethality in glioblastoma models. The findings highlight a potential therapeutic strategy targeting apoptotic resistance, with implications for overcoming treatment barriers in GBM.
Chemical Induction of Lhx1 in Mouse ES Cells via DNMT Inhibi
2026-07-10
This study demonstrates that mouse embryonic stem cells can be differentiated into spermatogonia-like cells with increased Lhx1 expression through a protocol combining dual pathway inhibition and targeted chemical intervention, including the DNA methyltransferase inhibitor RG108. These findings provide a significant advance in modeling early male germline development in vitro and open new avenues for dissecting the molecular basis of spermatogonial stem cell specification.
ICG001 and Wnt/β-Catenin Inhibition: Precision Tools for Fib
2026-07-09
This article explores the mechanistic and translational value of ICG001—a selective Wnt/β-catenin pathway inhibitor—in dissecting epithelial–mesenchymal transition (EMT) and fibrosis, with strategic insights for researchers aiming to bridge preclinical models and therapeutic innovation. Integrating the latest mechanistic findings on the MMP7–E-cadherin/β-catenin axis, we outline practical protocols, competitive differentiation, and forward-looking perspectives for translational science.
MMP7 Drives EMT and Liver Fibrosis via E-cadherin/β-Catenin
2026-07-09
This study uncovers how MMP7 promotes liver fibrosis in biliary atresia by inducing epithelial–mesenchymal transition (EMT) through E-cadherin cleavage and β-catenin nuclear translocation. The findings reveal a mechanistic link between MMP7 activity and Wnt/β-catenin pathway dysregulation, highlighting potential therapeutic avenues for targeting fibrosis in pediatric liver disease.
Octenidine Dihydrochloride: Applied Antimicrobial Protocols
2026-07-08
Octenidine dihydrochloride delivers robust and reproducible membrane disruption for antimicrobial research, with workflow flexibility across bacterial, fungal, and viral assays. Here, we detail setup nuances, advanced applications, and troubleshooting strategies to help researchers leverage this high-purity compound for next-generation antiseptic investigations.
Cyclophosphamide in Cancer Research: Protocols and Innovatio
2026-07-08
Cyclophosphamide stands out as a gold-standard alkylating chemotherapeutic agent for both apoptosis induction in cancer cells and immune modulation in translational research. This article delivers actionable workflows, advanced troubleshooting insights, and evidence-driven protocol enhancements to help researchers maximize reproducibility and data quality using APExBIO's Cyclophosphamide.
Eltanexor (KPT-8602): Advanced Workflows in Cancer Research
2026-07-07
Eltanexor (KPT-8602) empowers translational oncology labs with a second-generation, orally bioavailable XPO1 inhibitor that excels in both hematologic and solid tumor models. This article details how to maximize its performance in experimental workflows, resolve common bottlenecks, and leverage the latest mechanistic insights for high-impact discoveries.
MK 0893: Mechanism, Evidence, and Workflow for Glucagon Rece
2026-07-07
MK 0893 is a potent, competitive, and reversible glucagon receptor antagonist studied for type 2 diabetes research. Its unique binding to an extra-helical allosteric site inhibits GCGR activation and cAMP signaling. This article synthesizes current evidence, protocol integration, and practical limits for laboratory and translational workflows.
IWP-2 in Cancer Research: Unraveling Wnt Pathway Dependencie
2026-07-06
Explore how IWP-2, a potent Wnt production inhibitor, uniquely advances cancer research by dissecting Wnt/β-catenin signaling dependencies. This article provides a scientific deep-dive into IWP-2's mechanisms, practical assay considerations, and the latest insights from epigenetics.
462 records 12/31 page Previous Next First page 上5页 1112131415 下5页 Last page